The Company paid Neuren an upfront license fee of $ 10.0 million and it may be required to pay up to an additional $ 455.0 million in milestone payments based on the achievement of certain developmen…
The Company paid Saniona an upfront fee of $ 28.0 million and it may be required to pay up to $ 582.0 million in milestone payments based on the achievement of certain development and annual net sale…
The Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first quarter of 2022 as there is no altern…
Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the …
Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the …
ACADIA Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ACAD-DEBT
Debt stack $50.8M
90%
Market cache reports total debt of $50.8M.
ACAD-DEBT-7450
Warrants outstanding: 0.35
90%
xbrl warrant detail from xbrl 2012-12-31.
ACADIA Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ACADIA Pharmaceuticals Inc..
ACADIA Pharmaceuticals Inc. Ownership
Holder
Name
Confidence
Evidence
ACAD-OWNER-BAKER-BROS-ADVISORS-LP
BAKER BROS. ADVISORS LP
90%
13F overlay lists BAKER BROS. ADVISORS LP as top holder; 346 tracked holders.
ACADIA Pharmaceuticals Inc. Extended Supply Chain Network
